Free Trial
→ Trump Orders 'National Digital Asset Stockpile' (From Crypto 101 Media) (Ad) Buy MLYS Stock  Free MLYS Stock Alerts

Mineralys Therapeutics (MLYS) Financials

Mineralys Therapeutics logo
$14.09 +0.56 (+4.14%)
As of 04:00 PM Eastern
Compare
Annual Income Statements for Mineralys Therapeutics

Annual Income Statements for Mineralys Therapeutics

This table shows Mineralys Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -30 -72 -178
Consolidated Net Income / (Loss)		 -30 -72 -178
Net Income / (Loss) Continuing Operations		 -30 -72 -178
Total Pre-Tax Income 		-30 -72 -178
Total Operating Income		 -31 -85 -192
Total Gross Profit		 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 31 85 192
Selling, General & Admin Expense		 5.23 14 24
Research & Development Expense		 26 70 169
Total Other Income / (Expense), net		 1.68 13 15
Interest & Investment Income		 1.68 13 15
Other Income / (Expense), net		 0.00 - 0.01
Basic Earnings per Share		 ($5.77) ($1.99) ($3.66)
Weighted Average Basic Shares Outstanding		 5.17M 36.19M 48.54M
Diluted Earnings per Share		 ($5.77) ($1.99) ($3.66)
Weighted Average Diluted Shares Outstanding		 5.17M 36.19M 48.54M
Weighted Average Basic & Diluted Shares Outstanding		 - 49.63M 49.84M

Quarterly Income Statements for Mineralys Therapeutics

This table shows Mineralys Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 -6.68 - -13 -12 -23 -24 -32 -41 -56 -49
Consolidated Net Income / (Loss)		 -6.68 - -13 -12 -23 -24 -32 -41 -56 -49
Net Income / (Loss) Continuing Operations		 -6.68 - -13 -12 -23 -24 -32 -41 -56 -49
Total Pre-Tax Income 		-6.68 - -13 -12 -23 -24 -32 -41 -56 -49
Total Operating Income		 -7.42 - -15 -16 -26 -28 -35 -45 -60 -52
Total Operating Expenses		 7.42 - 15 16 26 28 35 45 60 52
Selling, General & Admin Expense		 1.36 - 2.65 3.85 3.77 4.03 4.61 5.90 6.12 7.20
Research & Development Expense		 6.06 - 12 12 22 24 31 39 54 45
Total Other Income / (Expense), net		 0.75 - 2.33 3.59 3.51 3.32 3.85 4.15 3.76 2.82
Interest & Investment Income		 0.74 - 2.33 3.59 3.51 3.32 3.85 4.15 3.77 2.81
Other Income / (Expense), net		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 -0.01 0.01
Basic Earnings per Share		 ($1.29) - ($0.51) ($0.31) ($0.57) ($0.60) ($0.70) ($0.83) ($1.13) ($1.00)
Weighted Average Basic Shares Outstanding		 5.18M 5.17M 24.76M 39.75M 39.93M 36.19M 44.90M 49.36M 49.82M 48.54M
Diluted Earnings per Share		 ($1.29) - ($0.51) ($0.31) ($0.57) ($0.60) ($0.70) ($0.83) ($1.13) ($1.00)
Weighted Average Diluted Shares Outstanding		 5.18M 5.17M 24.76M 39.75M 39.93M 36.19M 44.90M 49.36M 49.82M 48.54M
Weighted Average Basic & Diluted Shares Outstanding		 - 0.00 - - 41.11M 49.63M 49.65M 49.73M 49.77M 49.84M

Annual Cash Flow Statements for Mineralys Therapeutics

This table details how cash moves in and out of Mineralys Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Change in Cash & Equivalents		 77 -38 65
Net Cash From Operating Activities		 -29 -81 -166
Net Cash From Continuing Operating Activities		 -29 -81 -166
Net Income / (Loss) Continuing Operations		 -30 -72 -178
Consolidated Net Income / (Loss)		 -30 -72 -178
Depreciation Expense		 - 0.00 0.04
Amortization Expense		 -0.65 -6.87 -9.41
Non-Cash Adjustments To Reconcile Net Income		 0.46 5.06 11
Changes in Operating Assets and Liabilities, net		 0.77 -7.47 9.52
Net Cash From Investing Activities		 -22 -160 115
Net Cash From Continuing Investing Activities		 -22 -160 115
Purchase of Property, Plant & Equipment		 - 0.00 -0.10
Purchase of Investments		 -72 -348 -373
Sale and/or Maturity of Investments		 50 188 489
Net Cash From Financing Activities		 128 203 116
Net Cash From Continuing Financing Activities		 128 203 116
Repurchase of Common Equity		 - 0.00 -0.44
Issuance of Common Equity		 -1.63 203 116
Other Financing Activities, net		 0.00 0.19 0.30

Quarterly Cash Flow Statements for Mineralys Therapeutics

This table details how cash moves in and out of Mineralys Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 - 39 51 -37 -15 -37 41 -23 29 17
Net Cash From Operating Activities		 - -10 -13 -20 -19 -29 -19 -30 -50 -67
Net Cash From Continuing Operating Activities		 - -10 -13 -20 -19 -29 -19 -30 -50 -67
Net Income / (Loss) Continuing Operations		 - -9.07 -13 -12 -23 -24 -32 -41 -56 -49
Consolidated Net Income / (Loss)		 - -9.07 -13 -12 -23 -24 -32 -41 -56 -49
Depreciation Expense		 - - 0.00 - - - 0.01 0.01 0.01 0.02
Amortization Expense		 - -0.41 -0.86 -1.98 -1.96 -2.07 -2.51 -2.85 -2.71 -1.34
Non-Cash Adjustments To Reconcile Net Income		 - 0.22 0.75 1.28 1.58 1.46 2.19 2.87 3.14 3.13
Changes in Operating Assets and Liabilities, net		 - -0.92 -0.06 -7.54 4.11 -3.98 13 11 5.72 -20
Net Cash From Investing Activities		 - 50 -140 -16 4.01 -8.09 -56 7.74 80 84
Net Cash From Continuing Investing Activities		 - 50 -140 -16 4.01 -8.09 -56 7.74 80 84
Purchase of Investments		 - - -163 -56 -56 -73 -123 -127 -59 -64
Sale and/or Maturity of Investments		 - 50 23 40 60 65 68 135 139 148
Net Cash From Financing Activities		 - -1.07 204 -0.58 0.18 0.07 116 -0.15 -0.00 0.09
Net Cash From Continuing Financing Activities		 - -1.07 204 -0.58 0.18 0.07 116 -0.15 -0.00 0.09
Repurchase of Common Equity		 - - 0.00 - - - -0.06 -0.28 -0.04 -0.05
Issuance of Common Equity		 - -1.07 204 -0.58 - 0.06 116 0.08 - 0.08
Other Financing Activities, net		 - - 0.00 - 0.18 0.01 0.15 0.05 0.04 0.05

Annual Balance Sheets for Mineralys Therapeutics

This table presents Mineralys Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Total Assets		 114 252 206
Total Current Assets		 113 249 205
Cash & Equivalents		 88 49 114
Short-Term Investments		 22 187 84
Prepaid Expenses		 2.70 13 7.16
Plant, Property, & Equipment, net		 0.00 0.00 0.05
Total Noncurrent Assets		 1.63 2.53 0.50
Long-Term Investments		 0.00 2.48 0.00
Other Noncurrent Operating Assets		 1.63 0.05 0.50
Total Liabilities & Shareholders' Equity		 114 252 206
Total Liabilities		 8.07 10 15
Total Current Liabilities		 8.07 10 15
Accounts Payable		 1.91 0.60 0.48
Accrued Expenses		 6.16 9.88 14
Total Noncurrent Liabilities		 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -52 241 191
Total Preferred & Common Equity		 -52 241 191
Total Common Equity		 -52 241 191
Common Stock		 0.54 366 494
Retained Earnings		 -53 -125 -303

Quarterly Balance Sheets for Mineralys Therapeutics

This table presents Mineralys Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 278 347 318 268
Total Current Assets		 265 347 318 268
Cash & Equivalents		 86 90 68 97
Short-Term Investments		 167 248 243 166
Prepaid Expenses		 12 8.25 6.89 4.13
Plant, Property, & Equipment, net		 0.00 0.05 0.04 0.07
Total Noncurrent Assets		 12 0.38 0.45 0.45
Long-Term Investments		 12 0.00 0.00 0.00
Other Noncurrent Operating Assets		 0.05 0.38 0.45 0.45
Total Liabilities & Shareholders' Equity		 278 347 318 268
Total Liabilities		 14 19 28 31
Total Current Liabilities		 14 19 28 31
Accounts Payable		 5.57 4.26 1.71 3.11
Accrued Expenses		 7.97 15 27 28
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 264 328 290 237
Total Preferred & Common Equity		 264 328 290 237
Total Common Equity		 264 328 290 237
Common Stock		 364 484 487 491
Retained Earnings		 -100 -156 -197 -254

Annual Metrics and Ratios for Mineralys Therapeutics

This table displays calculated financial ratios and metrics derived from Mineralys Therapeutics' official financial filings.

Metric 2022 2023 2024
Growth Metrics		 - - -
Revenue Growth		 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -184.90% -120.45%
EBIT Growth		 0.00% -168.97% -127.27%
NOPAT Growth		 0.00% -168.93% -127.27%
Net Income Growth		 0.00% -141.28% -147.31%
EPS Growth		 0.00% 65.51% -83.92%
Operating Cash Flow Growth		 0.00% -177.79% -104.89%
Free Cash Flow Firm Growth		 0.00% 0.00% -93.01%
Invested Capital Growth		 0.00% 156.36% -429.22%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% -1,657.00% -13.04%
EBIT Q/Q Growth		 0.00% 0.00% -14.28%
NOPAT Q/Q Growth		 0.00% 0.00% -14.29%
Net Income Q/Q Growth		 0.00% 0.00% -16.02%
EPS Q/Q Growth		 0.00% 0.00% -12.27%
Operating Cash Flow Q/Q Growth		 0.00% -30.13% -29.48%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -35.03%
Invested Capital Q/Q Growth		 0.00% 212.09% 74.02%
Profitability Metrics		 - - -
Gross Margin		 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00%
Interest Burden Percent		 94.68% 84.93% 92.42%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -28.01% -41.38% -82.24%
Cash Return on Invested Capital (CROIC)		 0.00% -3,092.63% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 13.76% -22.49% -82.24%
Return on Equity Simple (ROE_SIMPLE)		 57.01% -29.81% -92.97%
Net Operating Profit after Tax (NOPAT)		 -22 -59 -135
NOPAT Margin		 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -7.05% -7.24% -19.73%
Return On Investment Capital (ROIC_SIMPLE)		 - -24.57% -70.42%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -31 -85 -192
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -32 -92 -202
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 0.00 1.47 3.20
Price to Tangible Book Value (P/TBV)		 0.00 1.47 3.20
Price to Revenue (P/Rev)		 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 54.37 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -1.04 -1.00 -1.01
Leverage Ratio		 1.08 1.05 1.06
Compound Leverage Factor		 1.02 0.89 0.98
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 149.14% 0.00% 0.00%
Common Equity to Total Capital		 -49.14% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 13.83 19.57 21.07
Noncontrolling Interest Sharing Ratio		 149.14% 45.65% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 13.98 23.76 14.02
Quick Ratio		 13.65 22.57 13.53
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 0.00 -65 -126
Operating Cash Flow to CapEx		 0.00% 0.00% -173,243.75%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 -3.74 2.11 -6.93
Invested Capital Turnover		 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 5.84 -9.04
Enterprise Value (EV)		 241 114 414
Market Capitalization		 192 354 613
Book Value per Share		 ($10.12) $5.87 $3.84
Tangible Book Value per Share		 ($10.12) $5.87 $3.84
Total Capital		 106 241 191
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -110 -239 -198
Capital Expenditures (CapEx)		 0.00 0.00 0.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.37 2.05 -7.48
Debt-free Net Working Capital (DFNWC)		 105 239 191
Net Working Capital (NWC)		 105 239 191
Net Nonoperating Expense (NNE)		 7.76 13 43
Net Nonoperating Obligations (NNO)		 -110 -239 -198
Total Depreciation and Amortization (D&A)		 -0.65 -6.87 -9.36
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.99) ($3.66)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 36.19M 48.54M
Adjusted Diluted Earnings per Share		 $0.00 ($1.99) ($3.66)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 36.19M 48.54M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 49.63M 49.84M
Normalized Net Operating Profit after Tax (NOPAT)		 -22 -59 -135
Normalized NOPAT Margin		 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -0.24%

Quarterly Metrics and Ratios for Mineralys Therapeutics

This table displays calculated financial ratios and metrics derived from Mineralys Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% 0.00% 0.00% 0.00% -280.58% -7,162.68% -139.75% -170.96% -122.48% -78.25%
EBIT Growth		 0.00% 0.00% 0.00% 0.00% -254.13% 0.00% -136.73% -187.06% -128.81% -86.77%
NOPAT Growth		 0.00% 0.00% 0.00% 0.00% -253.94% 0.00% -136.73% -187.05% -128.77% -86.81%
Net Income Growth		 0.00% 0.00% 0.00% 0.00% -240.82% 0.00% -149.90% -237.81% -147.55% -100.69%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 55.81% 0.00% -37.25% -167.74% -98.25% -66.67%
Operating Cash Flow Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -184.52% -49.82% -47.88% -163.71% -130.64%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4.65% -7.78%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 156.36% 0.00% 0.00% -1,320.18% -429.22%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 94.47% -3,751.71% -12.18% -59.38% -5.46% -27.16% -26.79% -30.86% 15.51%
EBIT Q/Q Growth		 0.00% 100.00% 0.00% -5.34% -66.98% -5.47% -27.61% -27.73% -33.10% 13.91%
NOPAT Q/Q Growth		 0.00% 100.00% 0.00% -5.34% -66.97% -5.47% -27.61% -27.73% -33.07% 13.87%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 3.70% -87.46% -7.16% -29.19% -30.17% -37.37% 13.13%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 39.22% -83.87% -5.26% -16.67% -18.57% -36.14% 11.50%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -25.42% -59.58% 6.65% -52.28% 33.96% -57.51% -66.48% -33.19%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -52.83% 43.60% 25.54% -63.07% -57.41%
Invested Capital Q/Q Growth		 0.00% 0.00% 100.00% 0.00% 0.00% 212.09% -599.76% -99.81% -26.88% 74.02%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 90.01% 0.00% 84.41% 77.16% 86.63% 88.01% 89.10% 90.81% 93.72% 94.57%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -28.01% 0.00% 0.00% 0.00% -41.38% -55.36% -82.50% -61.19% -82.24%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -3,092.63% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 13.76% 0.00% 0.00% 0.00% -22.49% -55.36% -82.50% -61.19% -82.24%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -27.68% -41.25% -64.68% 0.00%
Net Operating Profit after Tax (NOPAT)		 -5.20 0.00 -10 -11 -18 -19 -25 -32 -42 -36
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.00% 0.00% 0.00% -3.29% -2.86% -3.99% -6.04% -5.39% -5.81%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -8.04% - - - -18.95%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -7.42 0.00 -15 -16 -26 -28 -35 -45 -60 -52
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -7.42 -0.41 -16 -18 -28 -30 -38 -48 -63 -53
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 1.47 1.95 2.00 2.54 3.20
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 1.47 1.95 2.00 2.54 3.20
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 54.37 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.04 0.00 0.00 -1.01 -1.00 -1.03 -1.07 -1.06 -1.01
Leverage Ratio		 0.00 1.08 0.00 0.00 1.05 1.05 1.06 1.10 1.09 1.06
Compound Leverage Factor		 0.00 0.00 0.00 0.00 0.91 0.93 0.94 1.00 1.02 1.00
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 149.14% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -49.14% 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 14.73 0.00 0.00 0.00 20.32 20.19 12.03 10.53 23.32
Noncontrolling Interest Sharing Ratio		 0.00% 149.14% 0.00% 0.00% 0.00% 45.65% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 13.98 0.00 0.00 19.60 23.76 18.06 11.20 8.55 14.02
Quick Ratio		 0.00 13.65 0.00 0.00 18.74 22.57 17.63 10.96 8.42 13.53
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 0.00 0.00 -17 -25 -14 -11 -17 -27
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -32,438.98% 0.00% -135,637.84% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 -3.74 0.00 0.00 -1.88 2.11 -11 -21 -27 -6.93
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 0.00 0.00 0.00 -1.88 5.84 -11 -21 -25 -9.04
Enterprise Value (EV)		 0.00 241 188 0.00 0.00 114 302 270 339 414
Market Capitalization		 192 192 188 0.00 0.00 354 641 581 602 613
Book Value per Share		 $0.00 ($10.12) $0.00 $0.00 $6.61 $5.87 $6.61 $5.84 $4.76 $3.84
Tangible Book Value per Share		 $0.00 ($10.12) $0.00 $0.00 $6.61 $5.87 $6.61 $5.84 $4.76 $3.84
Total Capital		 0.00 106 0.00 0.00 264 241 328 290 237 191
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -110 0.00 0.00 -266 -239 -339 -311 -264 -198
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.06 0.00 0.04 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -5.37 0.00 0.00 -1.93 2.05 -11 -22 -27 -7.48
Debt-free Net Working Capital (DFNWC)		 0.00 105 0.00 0.00 252 239 328 290 236 191
Net Working Capital (NWC)		 0.00 105 0.00 0.00 252 239 328 290 236 191
Net Nonoperating Expense (NNE)		 1.48 0.00 2.15 1.13 4.37 4.99 6.75 9.40 14 13
Net Nonoperating Obligations (NNO)		 0.00 -110 0.00 0.00 -266 -239 -339 -311 -264 -198
Total Depreciation and Amortization (D&A)		 0.00 -0.41 -0.86 -1.98 -1.96 -2.07 -2.50 -2.84 -2.70 -1.32
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($0.57) ($0.60) ($0.70) ($0.83) ($1.13) ($1.00)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 5.17M 0.00 0.00 39.93M 36.19M 44.90M 49.36M 49.82M 48.54M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($0.57) ($0.60) ($0.70) ($0.83) ($1.13) ($1.00)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 5.17M 0.00 0.00 39.93M 36.19M 44.90M 49.36M 49.82M 48.54M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 0.00 41.11M 49.63M 49.65M 49.73M 49.77M 49.84M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.20 0.00 -10 -11 -18 -19 -25 -32 -42 -36
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.24%

Frequently Asked Questions About Mineralys Therapeutics' Financials

When does Mineralys Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Mineralys Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Mineralys Therapeutics' net income changed over the last 2 years?

Mineralys Therapeutics' net income appears to be on an upward trend, with a most recent value of -$177.81 million in 2024, rising from -$29.80 million in 2022. The previous period was -$71.90 million in 2023.

What is Mineralys Therapeutics's operating income?
Mineralys Therapeutics's total operating income in 2024 was -$192.40 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $192.40 million
How has Mineralys Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Mineralys Therapeutics' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Mineralys Therapeutics have?

Mineralys Therapeutics' total liabilities were at $14.65 million at the end of 2024, a 39.7% increase from 2023, and a 81.6% increase since 2022.

How much cash does Mineralys Therapeutics have?

In the past 2 years, Mineralys Therapeutics' cash and equivalents has ranged from $49.30 million in 2023 to $114.09 million in 2024, and is currently $114.09 million as of their latest financial filing in 2024.

How has Mineralys Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Mineralys Therapeutics' book value per share changed from -10.12 in 2022 to 3.84 in 2024, a change of -138.0%.


Related Companies

This page (NASDAQ:MLYS) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners
Trump’s Bitcoin Reserve is No Accident…
Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...
Crypto 101 Media | Sponsored
James Altucher: Do not invest in AI unless…
I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...
Paradigm Press | Sponsored
The Exact July Date the AI Correction Will End?
AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...
Brownstone Research | Sponsored
This Is The Moment You Betray Trump (Or Prove Them Wrong)
They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...
Colonial Metals | Sponsored
Trump’s treachery
Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...
Porter & Company | Sponsored
Two Unmistakable Patterns Return…
The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...
Golden Portfolio | Sponsored